Integrated Immune Engineering for Poor Prognosis Cancers

摘要 有效免疫治疗的一个关键限制是免疫细胞与癌细胞的物理接触。我们 建议开发基于免疫和肿瘤的多尺度肿瘤模拟器来预测肿瘤动力学 活细胞显微镜定量测量细胞迁移和净增殖。肿瘤 模拟器将由生物医学工程师与免疫学家和 基因工程师正在为胰腺导管腺癌和 胶质母细胞瘤。肿瘤模拟器将成为一个帮助指导免疫治疗的计算平台 开发等将演变为一个免疫治疗模拟器。此外，我们将整合州- 最先进的基因组工程和微环境工程带来一整套工程 关于模拟器开发的途径。总而言之，模拟器将用于制造 定量的、可测试的预测，然后使用药理学和遗传学进行实验测试 微扰。通过迭代模型开发，我们将检验我们的中心假设，即免疫细胞接近 是有效的抗肿瘤免疫反应的主要决定因素，并且限制了有效的免疫治疗。 实体瘤的症状。总之，我们的计划项目将开发一个全面的基于生物物理学的模拟器 以预测肿瘤进展并加速免疫疗法的发展。

ABSTRACT A key limitation to effective immunotherapy is the physical access of immune cells to the cancer cells. We propose to develop a multiscale tumor simulator to predict tumor dynamics based on immune and cancer cell migration and net proliferation as measured quantitatively from live cell microscopy. The tumor simulator will be developed by biomedical engineers working in close collaboration with immunologists and genetic engineers who are developing immunotherapies for pancreatic ductal adenocarcinoma and glioblastoma. The tumor simulator will be a computational platform that will help guide immunotherapy development and so will evolve to become an immunotherapy simulator. In addition, we will integrate state- of-the-art genome engineering and microenvironmental engineering to bring a full suite of engineering approaches to bear on the simulator development. Together, the simulator will be used to make quantitative, testable predictions that are then tested experimentally using pharmacological and genetic perturbations. By iterative model development we will test our central hypothesis that immune cell proximity is a major determinant of effective anti-tumoral immune response, and limiting to effective immunotherapy of solid tumors. Altogether, our Program Project will develop a comprehensive biophysics-based simulator to predict tumor progression and accelerate immunotherapy development.